Cencora Inc - Kewajiban jangka dawa perusahaan COR

The global drug delivery sector remains crisis-resilient and is expanding through biopharmaceuticals, which supports Cencora, Inc. (COR), as growth is driven by specialty pharmaceuticals and an aging population. However, low margins and e-commerce expansion create significant risks. This long-term debt chart for the business on GURU.Markets illustrates the credit load, and this metric equals 10.63, allowing for an assessment of the issuer's financial stability.

COR Cencora: Utang jangka dawa perusahaan ing interval 21.02.2024 - 29.10.2026

AmerisourceBergen - rincian analitis lan metrik utama (COR)

- rega lan prakiraan konsensus rega:

Bagan owah-owahan rega cencora.com|COR - Bagan rega target

- data kapitalisasi pasar:

Biji pasar Cencora|COR - Nilai Perusahaan

- data kapitalisasi buku:

Nilai Buku saben Saham Cencora|COR - Kapitalisasi Buku|Rasio Kapitalisasi marang Aset Bersih cencora.com|COR - Gunggung Aset Perusahaan

- data utang lan likuiditas:

Utang marang Modal Cencora, Inc.|COR - Utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas AmerisourceBergen Corporation|COR - Gunggung utang perusahaan|Utang-utang marang nilai buku Cencora|COR - Utang jangka dawa perusahaan|Tanggungan utang jangka cendhak perusahaan Cencora

Pambiji fundamental:cencora.com (COR)

Operating cycle efficiency directly determines the company's ability to service its debt obligations. This metric measures the total volume of borrowings with a maturity of over one year, reflecting the pace of business recovery amid market stagnation. The stability of pharmaceutical logistics and the value of Cencora, Inc. (COR) human capital support the current value of 10.63. By analyzing the dynamics of the business's long-term debt capital, an investor can balance default risks against return potential.

Analisis pesaing